AbbVie (ABBV) Q3 2025 Financial Results Summary
Release Date: October 31, 2025
AbbVie Inc. (NYSE: ABBV) has announced its financial results for the third quarter ended September 30, 2025. The company’s quarterly performance highlighted both challenges and areas of growth across its diverse portfolio.
Key Financial Metrics
- Diluted Earnings Per Share (EPS):
- GAAP: $0.10 — a decrease of 88.6% compared to Q3 2024.
-
Adjusted: $1.86 — a decrease of 38.0% compared to Q3 2024, impacted by a $1.50 unfavorable impact from acquired IPR&D and milestone expenses.
-
Net Revenues:
- $15.776 billion — an increase of 9.1% on a reported basis, or 8.4% on an operational basis.
Portfolio Performance
- Immunology Portfolio:
-
Total Revenues: $7.885 billion
- Increase of 11.9% (reported), or 11.2% (operational).
- Skyrizi: $4.708 billion (46.8% increase reported).
- Rinvoq: $2.184 billion (35.3% increase reported).
- Humira: $993 million (decrease of 55.4% reported).
-
Neuroscience Portfolio:
-
Total Revenues: $2.841 billion
- Increase of 20.2% (reported), or 19.6% (operational).
- Vraylar: $934 million (6.7% increase).
- Botox Therapeutic: $985 million (16.1% increase).
- Combined Ubrelvy and Qulipta: $642 million (31.5% increase).
-
Oncology Portfolio:
-
Total Revenues: $1.682 billion
- Decrease of 0.3% (reported), or 1.3% (operational).
- Imbruvica: $706 million (decrease of 14.8%).
- Venclexta: $726 million (increase of 7.1%).
- Elahere: $170 million (increase of 23.3%).
-
Aesthetics Portfolio:
- Total Revenues: $1.193 billion
- Decrease of 3.7% (reported), or 4.2% (operational).
- Botox Cosmetic: $637 million (decrease of 4.9%).
- Juvederm: $253 million (decrease of 2.2%).
Expense and Margin Analysis
- Gross Margin:
- GAAP: 66.4%.
-
Adjusted: 83.9%.
-
Selling, General and Administrative (SG&A) Expense:
- GAAP: 22.6% of net revenues.
-
Adjusted: 21.6% of net revenues.
-
Research and Development (R&D) Expense:
- GAAP: 14.7% of net revenues.
-
Adjusted: 14.3% of net revenues.
-
Operating Margin:
- GAAP: 12.1%.
-
Adjusted: 30.9%.
-
Net Interest Expense: $667 million.
-
Tax Rate:
- GAAP: 73.7%.
- Adjusted: 24.5%.
Outlook
- AbbVie has raised its guidance for Adjusted Diluted EPS for 2025 from a range of $10.38 – $10.58 to $10.61 – $10.65. This includes an unfavorable impact of $2.05 per share from the acquired IPR&D and milestone expenses incurred year-to-date through Q3 2025.
Shareholder Returns
- AbbVie announced a dividend increase of 5.5%, moving from $1.64 to $1.73 per share, effective from February 17, 2026, to shareholders of record as of January 16, 2026.
Recent Developments
- AbbVie received FDA approval for a supplemental New Drug Application for Rinvoq to treat adults with ulcerative colitis and Crohn’s disease.
- Positive Phase 3 results were reported for Rinvoq in treating severe alopecia areata and non-segmental vitiligo.
- The company completed acquisitions of Capstan Therapeutics and Gilgamesh Pharmaceuticals, enhancing its clinical pipeline.
Overall, while AbbVie has demonstrated robust growth in some portfolios, challenges in others, particularly regarding established products like Humira, are noteworthy. The increase in dividends reflects the company’s ongoing commitment to shareholder returns amid these varied outcomes across its business segments.
Here are the extracted tables from the press release you provided:
Consolidated Statements of Earnings
In millions, except per share data
| Third Quarter | Ended September 30 | Nine Months | Ended September 30 | |
|---|---|---|---|---|
| Net revenues | $15,776 | $14,460 | $44,542 | $41,232 |
| Cost of products sold | 5,304 | 4,212 | 13,652 | 12,508 |
| Selling, general and administrative | 3,569 | 4,205 | 10,115 | 10,897 |
| Research and development | 2,319 | 2,130 | 6,517 | 6,017 |
| Acquired IPR&D and milestones | 2,680 | 82 | 3,751 | 1,183 |
| Other operating income | — | — | -24 | — |
| Total operating costs and expenses | 13,872 | 10,629 | 34,011 | 30,605 |
| Operating earnings | 1,904 | 3,831 | 10,531 | 10,627 |
| Interest expense, net | 667 | 591 | 1,972 | 1,550 |
| Net foreign exchange loss (gain) | 20 | -3 | 47 | 2 |
| Other expense, net | 503 | 1,159 | 4,583 | 3,090 |
| Earnings before income tax expense | 714 | 2,084 | 3,929 | 5,985 |
| Income tax expense | 526 | 520 | 1,511 | 1,676 |
| Net earnings | 188 | 1,564 | 2,418 | 4,309 |
| Net earnings attributable to | 2 | 3 | 8 | 9 |
| noncontrolling interest | ||||
| Net earnings attributable to AbbVie Inc. | $186 | $1,561 | $2,410 | $4,300 |
| Diluted earnings per share attributable | $0.10 | $0.88 | $1.34 | $2.41 |
| to AbbVie Inc. | ||||
| Adjusted diluted earnings per sharea | $1.86 | $3.00 | $7.29 | $7.96 |
| Weighted-average diluted shares | 1,772 | 1,772 | 1,772 | 1,772 |
| outstanding |
Condensed Consolidated Balance Sheets
In millions
| AbbVie Inc. | Condensed Consolidated Balance Sheets | (Unaudited) | September 30 | December 31 |
|---|---|---|---|---|
| 2025 | 2024 | |||
| Assets: | ||||
| Current assets: | Cash and cash equivalents | $7,123 | $7,926 | |
| Trade receivables, net | 11,024 | 10,501 | ||
| Inventories | 3,258 | 3,042 | ||
| Other current assets | 1,376 | 1,070 | ||
| Total current assets | 22,781 | 22,539 | ||
| Property, plant and equipment, net | 8,955 | 8,372 | ||
| Intangible assets, net | 72,512 | 54,237 | ||
| Goodwill | 110,197 | 110,060 | ||
| Other assets | 4,739 | 6,080 | ||
| $219,184 | $201,288 | |||
| Liabilities and stockholders’ equity: | ||||
| Current liabilities: | Current portion of long-term debt | $5,564 | $12,556 | |
| Trade payables | 5,198 | 5,073 | ||
| Other current liabilities | 4,287 | 4,529 | ||
| Total current liabilities | 15,049 | 22,158 | ||
| Long-term debt, net | 78,341 | 55,089 | ||
| Other long-term liabilities | 4,657 | 4,297 | ||
| Stockholders’ equity: | Common stock and additional paid-in capital | 62,049 | 62,049 | |
| Retained earnings | 56,750 | 59,038 | ||
| Total stockholders’ equity | 118,799 | 121,087 | ||
| $219,184 | $201,288 |
